Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:5
|
作者
Peng, June S. [1 ,2 ]
LaPiano, Jessica [3 ]
Wang, Katy [4 ]
Attwood, Kristopher [4 ]
Skitzki, Joseph J. [5 ]
Kane, John M., III [1 ]
Francescutti, Valerie A. [1 ,5 ]
机构
[1] Roswell Pk Comprehens Canc Ctr, Dept Surg Oncol, Buffalo, NY 14203 USA
[2] Penn State Univ, Div Surg Oncol, Coll Med, Dept Surg, Hershey, PA 16801 USA
[3] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[4] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA
[5] McMaster Univ, Dept Surg, Hamilton, ON, Canada
关键词
MORBIDITY; THERAPY; TRIAL;
D O I
10.1245/s10434-021-10556-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Management of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has historically favored liberal fluid administration owing to lengthy duration of surgery and hyperthermia. This practice has been challenged in recent years with studies demonstrating improved outcomes with restrictive fluid administration. Methods Patients who underwent CS/HIPEC between March 2010 and September 2018 were included for analysis. Patients who received an above-median fluid rate (high-IVF) versus below-median fluid rate (low-IVF) were compared, and multivariate analyses were performed for length of stay, 90-day unplanned readmissions, and major complications. Results The 167 patients had a mean age of 56.7 +/- 11.4 years and body mass index of 29.5 +/- 6.9 kg/m(2). The median rate of total intraoperative crystalloid and colloid was 7.4 mL/kg/h. The low-IVF group had less blood loss (183 vs. 330 mL, p = 0.002), were less likely to need intraoperative vasopressor drip (2.4% vs. 11.9%, p = 0.018), and experienced fewer cardiac complications (2.4% vs. 10.7%, p = 0.031), pneumonias (0% vs. 6.0%, p = 0.024), and Clavien-Dindo grade 3-5 complications (14.5% vs. 33.3%, p = 0.004). Multivariate analyses identified bowel resection (HR 4.65, p = 0.0008) as a risk factor for 90-day unplanned readmission, while bowel resection, intraoperative fluid rate, and estimated blood loss were associated with increased length of stay. Conclusion Higher intraoperative fluid intake was associated with multiple postoperative complications and increased length of stay, and represents a potentially avoidable risk factor for morbidity in CS/HIPEC.
引用
收藏
页码:163 / 173
页数:11
相关论文
共 50 条
  • [1] Restrictive Intraoperative Fluid Rate is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    June S. Peng
    Jessica LaPiano
    Katy Wang
    Kristopher Attwood
    Joseph J. Skitzki
    John M. Kane
    Valerie A. Francescutti
    Annals of Surgical Oncology, 2022, 29 : 163 - 173
  • [2] ASO Visual Abstract: Restrictive Intraoperative Fluid Rate Is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Peng, June S.
    LaPiano, Jessica
    Wang, Katy
    Attwood, Kristopher
    Skitzki, Joseph J.
    Kane, John M., III
    Francescutti, Valerie A.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 3) : 638 - 639
  • [3] ASO Visual Abstract: Restrictive Intraoperative Fluid Rate Is Associated with Improved Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    June S. Peng
    Jessica LaPiano
    Katy Wang
    Kristopher Attwood
    Joseph J. Skitzki
    John M. Kane
    Valerie A. Francescutti
    Annals of Surgical Oncology, 2021, 28 : 638 - 639
  • [4] Restrictive Intraoperative Fluid Resuscitation During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Thampy, Chelsea Ann
    Edhayan, Elango
    Hagglund, Karen
    Nikzad, Mercedes
    Graham, Isabella Anne
    Booth, David
    Berri, Richard N.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 236 (05) : S113 - S113
  • [5] The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
    Shamavonian, Raphael
    McLachlan, Rohan
    Fisher, Oliver M.
    Valle, Sarah J.
    Alzahrani, Nayef A.
    Liauw, Winston
    Morris, David L.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 10 (02) : 235 - 243
  • [6] Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Jesús David Rubio-López
    Manuel Durán-Martínez
    Andrea Moreno-Blázquez
    Lidia Rodríguez-Ortiz
    Blanca Rufián-Andújar
    Francisca Valenzuela-Molina
    Ángela Casado Adam
    Juan M. Sánchez-Hidalgo
    Sebastián Rufián-Peña
    Antonio Romero-Ruiz
    J Briceño-Delgado
    Álvaro Arjona-Sánchez
    Langenbeck's Archives of Surgery, 408
  • [7] Intraoperative metabolic changes associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    David Rubio-Lopez, Jesus
    Duran-Martinez, Manuel
    Moreno-Blazquez, Andrea
    Rodriguez-Ortiz, Lidia
    Rufian-Andujar, Blanca
    Valenzuela-Molina, Francisca
    Casado Adam, Angela
    Sanchez-Hidalgo, Juan M.
    Rufian-Pena, Sebastian
    Romero-Ruiz, Antonio
    Briceno-Delgado, J.
    Arjona-Sanchez, Alvaro
    LANGENBECKS ARCHIVES OF SURGERY, 2023, 408 (01)
  • [8] The impact on postoperative outcomes of intraoperative fluid management strategies during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
    Dranichnikov, P.
    Semenas, E.
    Cashin, P. H.
    Graf, W.
    EJSO, 2023, 49 (08): : 1474 - 1480
  • [9] Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly
    Tabrizian, Parissa
    Jibara, Ghalib
    Shrager, Brian
    Franssen, Bernardo
    Yang, Ming-Jim
    Sarpel, Umut
    Hiotis, Spiros
    Labow, Daniel
    SURGICAL ONCOLOGY-OXFORD, 2013, 22 (03): : 184 - 189
  • [10] Fluid Administration and Morbidity in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Eng, O. S.
    Dumitra, S.
    O'Leary, M.
    Raoof, M.
    Wakabayashi, M.
    Dellinger, T. D.
    Han, E.
    Lee, S.
    Paz, I. B.
    Lee, B.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S78 - S78